Over a Baltimore Crab Cake Platter, Our Tech Guru Told Me About This Surging Biotech
Today marks exactly two months since we recommended Emergent BioSolutions Inc. (NYSE: EBS) – which we pitched as an “immunotherapy stock with a twist.”
In that short stretch, Emergent is up 25.5%. That’s an annualized return of 153%.
And there’s more to come…
Join the conversation. Click here to jump to comments…
About the Author
Shah Gilani is the Event Trading Specialist for Money Map Press. He provides specific trading recommendations in Capital Wave Forecast, where he predicts gigantic "waves" of money forming and shows you how to play them for the biggest gains. In Short-Side Fortunes, Shah shows the "little guy" how to make massive size gains – sometimes in a single day – by flipping large asset classes like stocks, bonds, commodities, ETFs and more. He also writes our most talked-about publication, Wall Street Insights & Indictments, where he reveals how Wall Street's high-stakes game is really played.